1 / 1

Vernal Keratoconjunctivitis Market

In 2017, the total prevalent population of Vernal Keratoconjunctivitis in the major markets (which includes the USA, Germany, France, the UK, Italy, Spain, Japan, China, Egypt, Saudi Arabia, and Russia) was found to be 4,752,356 and is expected to increase during the forecast period 2017-2030.<br><br>The market size of Vernal Keratoconjunctivitis in the major markets (i.e. 7MM, China, Egypt, Saudi Arabia, and Russia) was USD 307.89 Million in 2017.<br><br>The key factors such as rise in prevalence, disease awareness & diagnosis, and research & development are expected to drive the VKC market forward in the coming years. <br><br>The key players in the Vernal Keratoconjunctivitis market include Allakos Inc., iCo Therapeutics, Akari Therapeutics, Santen, Novartis, Alcon, Senju Pharmaceutical, and many others.<br><br>For more detailed information on Vernal Keratoconjunctivitis market, visit: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market

DelveInsight
Download Presentation

Vernal Keratoconjunctivitis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related